Mirum Pharmaceuticals, Inc.
MIRM
$100.64
$1.871.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.02% | 50.19% | 54.74% | 53.66% | 62.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.02% | 50.19% | 54.74% | 53.66% | 62.33% |
| Cost of Revenue | 25.47% | 22.11% | 22.78% | 12.96% | 22.81% |
| Gross Profit | 48.94% | 58.53% | 64.97% | 68.97% | 77.49% |
| SG&A Expenses | 37.43% | 37.97% | 27.10% | 25.14% | 28.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.39% | 41.98% | 26.84% | 26.20% | 29.08% |
| Operating Income | -75.18% | 1.69% | 80.44% | 61.66% | 51.97% |
| Income Before Tax | -1,394.98% | -950.60% | 75.35% | 58.33% | 46.61% |
| Income Tax Expenses | 122.05% | -3.69% | 87.96% | -67.61% | -30.64% |
| Earnings from Continuing Operations | -1,368.86% | -932.90% | 73.43% | 58.50% | 46.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,368.86% | -932.90% | 73.43% | 58.50% | 46.35% |
| EBIT | -75.18% | 1.69% | 80.44% | 61.66% | 51.97% |
| EBITDA | -134.33% | 4.76% | 111.11% | 82.76% | 68.61% |
| EPS Basic | -1,095.45% | -739.41% | 74.46% | 61.38% | 51.46% |
| Normalized Basic EPS | -57.03% | 16.00% | 81.85% | 24.56% | 14.01% |
| EPS Diluted | -1,094.74% | -739.34% | 73.60% | 61.14% | 51.43% |
| Normalized Diluted EPS | -57.56% | 15.62% | 81.54% | 23.98% | 14.01% |
| Average Basic Shares Outstanding | 15.03% | 9.40% | 5.27% | 7.63% | 10.09% |
| Average Diluted Shares Outstanding | 18.30% | 12.72% | 8.62% | 11.10% | 10.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |